Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 8, Issue 15, Pages 2615-2624Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.8.15.2615
Keywords
MAO-B inhibitor; motor fluctuation; Parkinson's disease; Zydis selegiline
Categories
Ask authors/readers for more resources
Selegiline, a selective monciamine oxidase-B inhibitor, has been used for decades in the treatment of Parkinson's disease. The recent development of an orally disintegrating dosage form using Zydis technology allows pregastric drug absorption and, thus, greatly improving the pharmacodynamic and pharmacokinetic drug profiles. This new formulation provides higher drug bioavailability and a substantially reduced concentration of active metabolites. As an adjunct to levoclopa, Zydis selegiline is shown to be a safe and effective therapy in patients with motor fluctuations and wearing off. This review outlines the advantages of a Zydis formulation in Parkinson's disease and the evidence supporting the use of Zydis selegiline for motor fluctuations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available